What defines our path for today and the future is our four-key strategic imperatives:
- Be the partner of choice and licensee for research based Pharmaceutical, Biopharmaceutical companies seeking to market their FDA, EMA/European and Japanese PMDA approved therapeutics, providing a "one stop" and complete AfMET regional solution.
- Be the preferred commercial partner and representative for companies seeking
- Wider regional access to their existing products
- Sell or Promote tail-end products
- Exit a therapeutic area
- Create second brand
- Create a portfolio of innovative Molecular Diagnostic devices (MDx) and Point-of-Care Diagnostics (POC) that envisage the delivery of future health care and personalized medicine.
- Introduce NewBridge's own brands in consumer and specialty branded generics, complimentary to our core model servicing research based companies